Pharma Focus Europe

Curia Enhances Cell Line Development Services With the Innovative CHOZN Platform

Wednesday, June 21, 2023

Curia, a leading contract research, development, and manufacturing organization, has recently entered into a licensing agreement with MilliporeSigma, the North American Life Sciences Business of Merck KGaA, Darmstadt, Germany. This agreement grants Curia and its clients the rights to utilize the CHOZN® GS-/- cell line for the production of therapeutic proteins and antibodies. Following the agreement, Curia has seamlessly integrated the CHOZN GS-/- cell line into its cell line development workflow, making it immediately accessible to its customers.

The CHOZN® platform is a mammalian cell expression system derived from Chinese Hamster Ovary (CHO) cells. It offers a streamlined and efficient approach for selecting and scaling up high-producing clones to produce biologics and therapeutic recombinant proteins. The platform includes high-performing CHO cell lines, optimized expression vectors, specialized media and feeds, and robust protocols. The GS knockout (GS-/-) cell line within the CHOZN platform is specifically designed to simplify the selection, identification, and scale-up of high-producing clones suitable for the Good Manufacturing Practice (GMP) manufacturing of recombinant protein drugs.

Christopher Conway, President of R&D at Curia, expressed enthusiasm about the partnership, stating, "We are continuously enhancing our biologics development offerings, from discovery through clinical manufacturing." He emphasized the value of the CHOZN GS-/- cell line platform, stating that it adds a widely accepted and commercially viable cell line to Curia's capabilities. Conway further explained that their integrated offering accelerates the production of therapeutic proteins and antibodies, while also providing optimal flexibility through seamless technology transfer.

Curia's team of experts in protein and antibody development has a strong track record of accelerating progress in this field. Depending on the manufacturability of the candidates, they have achieved timelines as short as 12 months from cell line development to phase I drug substance.

The addition of the CHOZN platform strengthens Curia's portfolio by complementing their existing proprietary CHO cell line. This expansion provides customers with a highly versatile and widely applicable solution for their biologics development needs.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva